Hepatitis C Clinical Trial
Official title:
A Patient-Centered Intervention to Increase Screening of Hepatitis B and C Among Asian Americans
Verified date | July 2020 |
Source | University of California, San Francisco |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Liver cancer and hepatitis B are health disparities for Asian Americans, and hepatitis C is a
rising problem. Little is known about how to improve the quality of health care Asian
Americans receive for viral hepatitis. Technology, specifically mobile applications, can
provide a flexible and efficient way to address these challenges. This project seeks to
develop, implement, and test an intervention to increase hepatitis B and C screening for
Asian Americans in 2 healthcare systems in San Francisco.
The research team will develop, implement, and evaluate the efficacy of an interactive,
patient- centered mobile app for use on a tablet computer to increase hepatitis B and C
screening among unscreened Asian Americans age 18 and older. The team will use their
experience in health promotion to develop the intervention by working with patients,
community leaders and advocates, clinical staff, healthcare providers, and healthcare system
administrators from a county safety net system and an academic primary care practice in the
San Francisco Bay Area. The mobile application will include video clips with a physician
(Video Doctor) addressing patient concerns regarding hepatitis B and C screening in the
patient's preferred language, English, Chinese, or Vietnamese. A patient who has not been
screened for hepatitis B will answer questions about his or her characteristics and
preferences using the mobile application. The mobile application will then show 30-60 seconds
video clips with messages that address the patient's responses related to hepatitis B
screening and that are delivered by an actor playing a physician. Those who are born between
1945 and 1965 also receive messages about hepatitis C screening. At the end, the tablet
computer will generate a provider alert to let the treating provider know what the patient's
preferences are regarding testing for viral hepatitis.
Once developed, the intervention will then be used in combination with a physician panel
notification and tested against physician panel notification only in a randomized controlled
trial to see which approach is better in increasing the rate of hepatitis B and C screening.
The team will also work with the 2 healthcare system to ensure that the interventions will be
practical and easily adopted once the study is over. The findings of this project will
greatly expand understanding about how to use technology- based interventions to improve
quality of healthcare in diverse patient populations.
Status | Completed |
Enrollment | 431 |
Est. completion date | July 30, 2017 |
Est. primary completion date | May 28, 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - ages 18+ years - identifies as Asian - Asian American, Chinese, or Vietnamese - speaks English, Chinese (Cantonese), or Vietnamese - does not have an electronic health record (EHR)-documented HBV screening test (defined as a hepatitis B surface antigen [HBsAg] test). - we select Chinese and Vietnamese because those are the 2 most common languages spoken by limited English-proficient Asian Americans Exclusion Criteria: - dementia or any conditions precluding understanding informed consent or using a touch screen with audio |
Country | Name | City | State |
---|---|---|---|
United States | University of California, San Francisco | San Francisco | California |
United States | Zuckerberg San Francisco General | San Francisco | California |
Lead Sponsor | Collaborator |
---|---|
University of California, San Francisco | Patient-Centered Outcomes Research Institute, San Francisco Hep B Free Campaign |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | EHR-documented hepatitis B surface antigen (HBsAg) test | The main outcome measure is an EHR-documented hepatitis B surface antigen (HBsAg) test at 3 months post-intervention. We chose screening for hepatitis B because, among adults, particularly immigrants or descendants of immigrants, it is the most important first step in the control of viral hepatitis B and lack of screening remains a significant problem. While many young adult Asian Americans born in the U.S. or who immigrated at a young age may have been vaccinated for hepatitis B as a child or prior to entering college, pre-vaccination testing may not have been done. Given the high rates of infection in their parents and the possibility of vertical transmission, all Asian Americans should be tested for chronic hepatitis B using the HBsAg test. All screening outcomes (test receipt) as well as test ordering by the healthcare providers will be collected from the medical record through the EHRs at 3-month post-intervention. | 3 months | |
Secondary | Knowledge about hepatitis B virus (HBV) and hepatitis C virus (HCV) | Data sources include the self-administered pre-intervention survey via a tablet computer, and the post-intervention phone survey administered by a research assistant, and EHR. All patient surveys will be done in the patient's preferred language (English, Chinese, or Vietnamese). Pre- and post-intervention survey data of secondary outcomes include: Knowledge (awareness of HBV and HCV, screening test, modes of transmission); Self-efficacy (perceived confidence in initiating conversation and request screening test from providers); Patient-Provider Communication Experiences (asked provider for HBV or HCV test, discussed HBV or HCV test with provider, receipt of provider recommendation to get a HBV or HCV test). | 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03686722 -
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
|
Phase 1 | |
Recruiting |
NCT04510246 -
Link Hepatitis C Notifications to Treatment in Tasmania
|
N/A | |
Completed |
NCT03413696 -
Effects of Health Literacy and HCV Knowledge on HCV Treatment Willingness in HIV-coinfected Patients
|
||
Completed |
NCT03118674 -
Harvoni Treatment Porphyria Cutanea Tarda
|
Phase 2 | |
Completed |
NCT03109457 -
Hepatitis C Virus Detection in Oral Squamous Cell Carcinoma
|
||
Completed |
NCT01458054 -
Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults
|
Phase 1 | |
Completed |
NCT03740230 -
An Observational Study of Maviret (Glecaprevir/Pibrentasvir) for Korean Chronic Hepatitis C Genotypes 1 to 6 Patients According to the Standard for Re-examination of New Drugs
|
||
Completed |
NCT03426787 -
Helping Empower Liver and Kidney Patients
|
N/A | |
Completed |
NCT03627299 -
Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors
|
Phase 4 | |
Completed |
NCT00006301 -
Immune Response to Hepatitis C Virus
|
||
Active, not recruiting |
NCT03949764 -
The Kentucky Viral Hepatitis Treatment Study
|
Phase 4 | |
Completed |
NCT03365635 -
Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C
|
Phase 4 | |
Recruiting |
NCT04405024 -
Pilot Study on the Feasibility of Systematic Hepatitis C Screening of Hospitalized Patients
|
N/A | |
Completed |
NCT04525690 -
Improving Inpatient Screening for Hepatitis C
|
N/A | |
Completed |
NCT04033887 -
Evaluation Study of RDTs Detecting Antibodies Against HCV
|
||
Withdrawn |
NCT04546802 -
HepATocellular Cancer Hcv Therapy Study
|
Phase 3 | |
Active, not recruiting |
NCT02961426 -
Strategic Transformation of the Market of HCV Treatments
|
Phase 2/Phase 3 | |
Completed |
NCT02992184 -
PoC-HCV Genedrive Viral Detection Assay Validation Study
|
N/A | |
Completed |
NCT03186313 -
A Study to Evaluate the Safety and Efficacy of the Combined Single Dose of Dactavira Plus Or Dactavira in Egyptian Adults With Chronic Genotype 4 HCV Infection
|
Phase 3 | |
Completed |
NCT02705534 -
Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1
|
Phase 3 |